Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 14 clients • 17 examiners • 9 art units • 0 of 19 (0%) have an AI response strategy ready
Knowles Intellectual Property Strategies, LLC operates in the Biotechnology & Pharmaceuticals technology area, where it has filed 794 career applications. The firm's resolved allowance rate is 78.92 percent, which measures the proportion of its cases that reach a grant. This history of 794 career applications provides the firm with a specific set of experiences in navigating the patent office's requirements for life sciences inventions.
The firm's prosecution process involves an average of 2.29 office actions per allowance. This metric indicates the typical number of interactions between the firm and patent examiners before an application reaches an allowance. For a practitioner, this average of 2.29 office actions per allowance suggests a prosecution cycle that typically involves two or three responses to the patent office. Currently, the firm is managing 12 pending office actions within its Biotechnology & Pharmaceuticals practice.
The 78.92 percent allowance rate and the 2.29 office actions per allowance serve as data points for understanding the firm's prosecution history. The 12 pending office actions represent the firm's current workload, which is smaller than the 794 career applications on record. These figures offer a data-grounded view of the firm's performance and its ongoing role in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (37%) |
| §102 only | 1 (5%) |
| Double-patenting + other | 6 (32%) |
| Multi-statute (no §101) | 4 (21%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 2 | 47.1% | +27.3% |
| HOWELL, THEODORE R | 2 | 66.8% | +25.3% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| LIEB, JEANETTE M | 1 | 79.9% | +17.2% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936782 | HALIDE-FREE AMMONIUM SILANES | VALENROD, YEVGENY | 15d |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
| 18769136 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | HAGHIGHATIAN, MINA | — |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | CHO, DAVID H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | HOWELL, THEODORE R | 78d overdue |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 7d |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | VALENROD, YEVGENY | 15d |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | DABKOWSKI, ERINNE R | 83d |
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | LIU, TRACY | — |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | LIEB, JEANETTE M | — |
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1628 | 4 |
| 1654 | 2 |
| 1615 | 2 |
| 1614 | 1 |
| 1613 | 1 |
| 1616 | 1 |
| 1624 | 1 |
| 1699 | 1 |
| 1611 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | Topikos Scientific, Inc. | LIU, TRACY | 1614 | §103 | Final Rejection | — | Pending | Dec 19, 2025 |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation | LIEB, JEANETTE M | 1654 | §103§112DP | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | DABKOWSKI, ERINNE R | 1654 | §103Other | Final Rejection | 83d | Pending | Sep 15, 2025 |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | 1615 | §103§112 | Final Rejection | 33d | Pending | Jul 21, 2025 |
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. | KOSAR, ANDREW D | §103 | Non-Final OA | — | Pending | Nov 22, 2024 | |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | Topikos Scientific, Inc. | VALENROD, YEVGENY | 1628 | §103§112 | Non-Final OA | 15d | Pending | Nov 04, 2024 |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Oculis Operations Sàrl | HUANG, GIGI GEORGIANA | 1613 | §103DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18792377 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl | ISMAIL, REHANA | §103DP | Non-Final OA | — | Pending | Aug 01, 2024 | |
| 18769136 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | Sensory Cloud, Inc. | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18749420 | SYNTHESIS OF PHOSPHATE DERIVATIVES | Nucana PLC | BERRY, LAYLA D | §103 | Non-Final OA | — | Pending | Jun 20, 2024 | |
| 18653750 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. | MCDOWELL, BRIAN E | 1624 | §102 | Non-Final OA | — | Pending | May 02, 2024 |
| 18592037 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. | CRAIGO, BAHAR ALAWI | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 | |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avilar Therapeutics, Inc. | CHO, DAVID H | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 | |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 3d overdue | Pending | Sep 29, 2023 |
| 18236836 | METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY | The United States Department of Veterans Affairs | HOWELL, THEODORE R | 1628 | §102§103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | Pharmacosmos Holding A/S | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Hoffmann-La Roche, Inc. | LEE, CHIHYI NMN | 1628 | §103 | Final Rejection | 32d overdue | Pending | Jun 16, 2023 |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | The United States Department of Veterans Affairs | HOWELL, THEODORE R | 1628 | §103 | Final Rejection | 78d overdue | Pending | May 09, 2023 |
| 17554940 | PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS | Pharmacosmos Holdings A/S | BAEK, BONG-SOOK | 1611 | §103§112DP | Final Rejection | — | Pending | Dec 17, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial